Anna Forsyth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Forsyth has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Suresh Daniel Muthukumaraswamy
University of Auckland
10 shared publications - Rachael L. Sumner
School of Pharmacy, University of Auckland, Auckland, New Zealand
5 shared publications - Carina Joy Donegan
Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, 22 Park Avenue, Grafton, Auckland, 1023, New Zealand
4 shared publications - David Benjamin Menkes
Department of Psychological Medicine, University of Auckland, Auckland, New Zealand
4 shared publications - Dimitri Daldegan-Bueno
School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand
4 shared publications - Frederick Sundram
University of Auckland, New Zealand
4 shared publications
Latest Publications
- Open Access
Linking human brain functional connectivity to underlying neurotransmission
The human brain is organized into interacting functional systems. Their underlying neurobiological mechanisms remain difficult to study in vivo 1,2 . Here, we adopt a topological framework to quantify the association between neurobiology and brain functional connectivity derived from both resting-state functional magnetic resonance imaging (rsfMRI) and magnetic encephalography (MEG). Across six healthy adult cohorts (n = 19–112), regional variation in rsfMRI connectivity robustly aligns with the distribution of neurotransmitter receptors and transporters. We find that low-frequency functional synchronization measured by rsfMRI is predominantly modulated by decreased regional availability of multiple receptors and transporters. These patterns are present in every single subject, replicate across all cohorts, and are mirrored in MEG, where high-frequency synchronization increases with availability of the same receptors and transporters. Most prominently, we observe noradrenergic modulation of functional connectivity in a sensorimotor-posterior-insular network that is consistently detected across individuals and is linked to autonomic arousal. In pharmacological and clinical samples, the associations are sensitive to manipulation of the respective neurotransmitter systems and are altered in patients with early psychosis, aligning with clinical symptomatology. These findings provide biological insight into typical and atypical functional organization of the human brain using a framework linking underlying neurobiology to the functional connectome (NEOFC).
Open AccessLinking human brain functional connectivity to underlying neurotransmission
The human brain is organized into interacting functional systems. Their underlying neurobiological mechanisms remain difficult to study in vivo 1,2 . Here, we adopt a topological framework to quantify the association between neurobiology and brain functional connectivity derived from both resting-state functional magnetic resonance imaging (rsfMRI) and magnetic encephalography (MEG). Across six healthy adult cohorts (n = 19–112), regional variation in rsfMRI connectivity robustly aligns with the distribution of neurotransmitter receptors and transporters. We find that low-frequency functional synchronization measured by rsfMRI is predominantly modulated by decreased regional availability of multiple receptors and transporters. These patterns are present in every single subject, replicate across all cohorts, and are mirrored in MEG, where high-frequency synchronization increases with availability of the same receptors and transporters. Most prominently, we observe noradrenergic modulation of functional connectivity in a sensorimotor-posterior-insular network that is consistently detected across individuals and is linked to autonomic arousal. In pharmacological and clinical samples, the associations are sensitive to manipulation of the respective neurotransmitter systems and are altered in patients with early psychosis, aligning with clinical symptomatology. These findings provide biological insight into typical and atypical functional organization of the human brain using a framework linking underlying neurobiology to the functional connectome (NEOFC).
- Open Access
- 18 February 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 145, 111645
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
- 18 February 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 145, 111645
Open AccessLSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
- Open Access
- 4 December 2025
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 15
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial
Background: Depressive disorders affect approximately 280 million globally, with many finding treatments ineffective or limited by side effects. Growing evidence suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing shows promise for major depressive disorder (MDD). However, research on LSD microdosing in clinical populations remains limited. Objectives: This study aimed to understand the experiences of individuals participating in an open-label trial of LSD microdosing for MDD. Design: Open-label pilot trial in target population (MDD; phase IIa). Methods: Seventeen participants with MDD completed an 8-week LSD microdosing regimen, dosing twice weekly. Following the intervention, participants underwent semi-structured interviews regarding their experiences. Data were analysed using thematic analysis. Results: Themes were grouped into five categories: enhanced self-determination, increased connectedness, improved cognitive processing, better emotional well-being, and negative effects. Conclusion: Reported effects appeared to reinforce one another; that is, self-determination led to feeling more connected, which enhanced cognitive processing and ultimately improved emotional well-being and reduced depressive symptoms. However, this effect was not universal; some individuals reported negative effects or no significant improvement from microdosing LSD. This variability may be due to individual differences in response, insufficient dosage, or the treatment’s lack of effectiveness for some individuals. The presence of side effects highlights the need for a careful titration protocol, while the lack of symptom improvement in some cases reinforces that microdosing is not a guaranteed solution, and expectations should remain realistic. The absence of a placebo control represents a key limitation as it precludes attribution of observed changes specifically to LSD. Trial registration: ANZCTR, ACTRN12623000486628. Registered on 12 May 2023 ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385758 ).
- 4 December 2025
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 15
Open AccessWhat is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial
Background: Depressive disorders affect approximately 280 million globally, with many finding treatments ineffective or limited by side effects. Growing evidence suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing shows promise for major depressive disorder (MDD). However, research on LSD microdosing in clinical populations remains limited. Objectives: This study aimed to understand the experiences of individuals participating in an open-label trial of LSD microdosing for MDD. Design: Open-label pilot trial in target population (MDD; phase IIa). Methods: Seventeen participants with MDD completed an 8-week LSD microdosing regimen, dosing twice weekly. Following the intervention, participants underwent semi-structured interviews regarding their experiences. Data were analysed using thematic analysis. Results: Themes were grouped into five categories: enhanced self-determination, increased connectedness, improved cognitive processing, better emotional well-being, and negative effects. Conclusion: Reported effects appeared to reinforce one another; that is, self-determination led to feeling more connected, which enhanced cognitive processing and ultimately improved emotional well-being and reduced depressive symptoms. However, this effect was not universal; some individuals reported negative effects or no significant improvement from microdosing LSD. This variability may be due to individual differences in response, insufficient dosage, or the treatment’s lack of effectiveness for some individuals. The presence of side effects highlights the need for a careful titration protocol, while the lack of symptom improvement in some cases reinforces that microdosing is not a guaranteed solution, and expectations should remain realistic. The absence of a placebo control represents a key limitation as it precludes attribution of observed changes specifically to LSD. Trial registration: ANZCTR, ACTRN12623000486628. Registered on 12 May 2023 ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385758 ).
- Open Access
- 24 November 2025
- Published by Akademiai Kiado Zrt. in Journal of Psychedelic Studies
- Vol. 9 (4) , 369-384
Tū Wairua: Development of an Indigenous Rongoā Māori approach to healing with psilocybin containing mushrooms
Psilocybin, a naturally occurring psychedelic compound found in certain fungi has long been used by Indigenous cultures within ritual and ceremony for healing and spiritual purposes (Spiers et al., 2024). While emerging evidence points to psychedelic agents being novel avenues for the treatment of substance use disorders, the predominantly Western medical models of psychedelic-assisted therapy (PAT) being developed lack Indigenous wisdom and input, raising concerns about cultural safety, efficacy, ownership, and continuing colonial dynamics. In Aotearoa (New Zealand), the enduring impacts of colonisation on Māori include the suppression of Indigenous wisdom, even as research affirming the knowledge and practice of traditional Māori healing is on the rise. The Tū Wairua project will explore the integration of rongoā Māori (traditional Māori healing practices) with PAT for addressing problematic methamphetamine use (PMU) in Māori communities. This Māori-led project is driven by Kaupapa Māori methodology, rongoā Māori conceptualisations of health and informed by biomedical psychedelic science. Based at Rangiwaho Marae in Te Tairāwhiti (Gisborne), a community with a high Māori population and a significant burden of PMU, the project aims to develop a decolonised culturally-appropriate approach to PAT to explore the efficacy of psilocybin in treating PMU. This research represents a shift toward health interventions that respect and extend Indigenous wisdom, addressing the unique needs of Māori communities. It also seeks to develop a skilled Māori workforce to continue these healing practices, and challenge current legislation that restricts the use of Indigenous psychedelic medicines. In creating sustainable pathways for collective healing through a community-driven, culturally-resonant PAT, Tū Wairua charts new directions in Indigenous-led psychedelic science.
- 24 November 2025
- Published by Akademiai Kiado Zrt. in Journal of Psychedelic Studies
- Vol. 9 (4) , 369-384
Open AccessTū Wairua: Development of an Indigenous Rongoā Māori approach to healing with psilocybin containing mushrooms
Psilocybin, a naturally occurring psychedelic compound found in certain fungi has long been used by Indigenous cultures within ritual and ceremony for healing and spiritual purposes (Spiers et al., 2024). While emerging evidence points to psychedelic agents being novel avenues for the treatment of substance use disorders, the predominantly Western medical models of psychedelic-assisted therapy (PAT) being developed lack Indigenous wisdom and input, raising concerns about cultural safety, efficacy, ownership, and continuing colonial dynamics. In Aotearoa (New Zealand), the enduring impacts of colonisation on Māori include the suppression of Indigenous wisdom, even as research affirming the knowledge and practice of traditional Māori healing is on the rise. The Tū Wairua project will explore the integration of rongoā Māori (traditional Māori healing practices) with PAT for addressing problematic methamphetamine use (PMU) in Māori communities. This Māori-led project is driven by Kaupapa Māori methodology, rongoā Māori conceptualisations of health and informed by biomedical psychedelic science. Based at Rangiwaho Marae in Te Tairāwhiti (Gisborne), a community with a high Māori population and a significant burden of PMU, the project aims to develop a decolonised culturally-appropriate approach to PAT to explore the efficacy of psilocybin in treating PMU. This research represents a shift toward health interventions that respect and extend Indigenous wisdom, addressing the unique needs of Māori communities. It also seeks to develop a skilled Māori workforce to continue these healing practices, and challenge current legislation that restricts the use of Indigenous psychedelic medicines. In creating sustainable pathways for collective healing through a community-driven, culturally-resonant PAT, Tū Wairua charts new directions in Indigenous-led psychedelic science.
- Open Access
- 5 November 2025
- Published by Elsevier in Neuropharmacology
- Vol. 283, 110762
LSD microdosing in major depressive disorder: results from an open-label trial
- 5 November 2025
- Published by Elsevier in Neuropharmacology
- Vol. 283, 110762
Open AccessLSD microdosing in major depressive disorder: results from an open-label trial
- Open Access
- 30 August 2025
- Published by Elsevier in Neuropharmacology
- Vol. 280, 110670
Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures
- 30 August 2025
- Published by Elsevier in Neuropharmacology
- Vol. 280, 110670
Open AccessQualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures
- Open Access
Local activity alterations in autism spectrum disorder correlate with neurotransmitter properties and ketamine induced brain changes
Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with altered resting-state brain function. An increased excitation-inhibition (E/I) ratio is discussed as a potential pathomechanism but in-vivo evidence of disturbed neurotransmission underlying these functional alterations remains scarce. We compared rs-fMRI local activity (LCOR) between ASD (N=405, N=395) and neurotypical controls (N=473, N=474) in two independent cohorts (ABIDE1 and ABIDE2). We then tested how these LCOR alterations co-localize with specific neurotransmitter systems derived from nuclear imaging and compared them with E/I changes induced by GABAergic (midazolam) and glutamatergic medication (ketamine). Across both cohorts, ASD subjects consistently exhibited reduced LCOR, particularly in higher-order default mode network nodes, alongside increases in bilateral temporal regions, the cerebellum, and brainstem. These LCOR alterations negatively co-localized with dopaminergic (D1, D2, DAT), glutamatergic (NMDA, mGluR5), GABAergic (GABAa) and cholinergic neurotransmission (VAChT). The NMDA-antagonist ketamine, but not GABAa-potentiator midazolam, induced LCOR changes which co-localize with D1, NMDA and GABAa receptors, thereby resembling alterations observed in ASD. We find consistent local activity alterations in ASD to be spatially associated with several major neurotransmitter systems. NMDA-antagonist ketamine induced neurochemical changes similar to ASD-related alterations, supporting the notion that pharmacological modulation of the E/I balance in healthy individuals can induce ASD-like functional brain changes. These findings provide novel insights into neurophysiological mechanisms underlying ASD. One Sentence Summary: Local activity alterations in ASD co-localize with glutamatergic and GABAergic neurotransmission and were similar to ketamine-induced brain changes.
Open AccessLocal activity alterations in autism spectrum disorder correlate with neurotransmitter properties and ketamine induced brain changes
Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with altered resting-state brain function. An increased excitation-inhibition (E/I) ratio is discussed as a potential pathomechanism but in-vivo evidence of disturbed neurotransmission underlying these functional alterations remains scarce. We compared rs-fMRI local activity (LCOR) between ASD (N=405, N=395) and neurotypical controls (N=473, N=474) in two independent cohorts (ABIDE1 and ABIDE2). We then tested how these LCOR alterations co-localize with specific neurotransmitter systems derived from nuclear imaging and compared them with E/I changes induced by GABAergic (midazolam) and glutamatergic medication (ketamine). Across both cohorts, ASD subjects consistently exhibited reduced LCOR, particularly in higher-order default mode network nodes, alongside increases in bilateral temporal regions, the cerebellum, and brainstem. These LCOR alterations negatively co-localized with dopaminergic (D1, D2, DAT), glutamatergic (NMDA, mGluR5), GABAergic (GABAa) and cholinergic neurotransmission (VAChT). The NMDA-antagonist ketamine, but not GABAa-potentiator midazolam, induced LCOR changes which co-localize with D1, NMDA and GABAa receptors, thereby resembling alterations observed in ASD. We find consistent local activity alterations in ASD to be spatially associated with several major neurotransmitter systems. NMDA-antagonist ketamine induced neurochemical changes similar to ASD-related alterations, supporting the notion that pharmacological modulation of the E/I balance in healthy individuals can induce ASD-like functional brain changes. These findings provide novel insights into neurophysiological mechanisms underlying ASD. One Sentence Summary: Local activity alterations in ASD co-localize with glutamatergic and GABAergic neurotransmission and were similar to ketamine-induced brain changes.
- Open Access
- 24 February 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-10
Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine
Revealing the acute cortical pharmacodynamics of an antidepressant dose of ketamine in humans with depression is key to determining the specific mechanism(s) of action for alleviating symptoms. While the downstream effects are characterised by increases in plasticity and reductions in depressive symptoms—it is the acute response in the brain that triggers this cascade of events. Computational modelling of cortical interlaminar and cortico-cortical connectivity and receptor dynamics provide the opportunity to interrogate this question using human electroencephalography (EEG) data recorded during a ketamine infusion. Here, resting-state EEG was recorded in a group of 30 patients with major depressive disorder (MDD) at baseline and during a 0.44 mg/kg ketamine dose comprising a bolus and infusion. Fronto-parietal connectivity was assessed using dynamic causal modelling to fit a thalamocortical model to hierarchically connected nodes in the medial prefrontal cortex and superior parietal lobule. We found a significant increase in parietal-to-frontal AMPA-mediated connectivity and a significant decrease in the frontal GABA time constant. Both parameter changes were correlated across participants with the antidepressant response to ketamine. Changes to the NMDA receptor time constant and inhibitory intraneuronal input into superficial pyramidal cells did not survive correction for multiple comparisons and were not correlated with the antidepressant response. These results provide evidence that the antidepressant effects of ketamine may be mediated by acute fronto-parietal connectivity and GABA receptor dynamics. Furthermore, it supports the large body of literature suggesting the acute mechanism underlying ketamine’s antidepressant properties is related to GABA-A and AMPA receptors rather than NMDA receptor antagonism.
- 24 February 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-10
Open AccessNeurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine
Revealing the acute cortical pharmacodynamics of an antidepressant dose of ketamine in humans with depression is key to determining the specific mechanism(s) of action for alleviating symptoms. While the downstream effects are characterised by increases in plasticity and reductions in depressive symptoms—it is the acute response in the brain that triggers this cascade of events. Computational modelling of cortical interlaminar and cortico-cortical connectivity and receptor dynamics provide the opportunity to interrogate this question using human electroencephalography (EEG) data recorded during a ketamine infusion. Here, resting-state EEG was recorded in a group of 30 patients with major depressive disorder (MDD) at baseline and during a 0.44 mg/kg ketamine dose comprising a bolus and infusion. Fronto-parietal connectivity was assessed using dynamic causal modelling to fit a thalamocortical model to hierarchically connected nodes in the medial prefrontal cortex and superior parietal lobule. We found a significant increase in parietal-to-frontal AMPA-mediated connectivity and a significant decrease in the frontal GABA time constant. Both parameter changes were correlated across participants with the antidepressant response to ketamine. Changes to the NMDA receptor time constant and inhibitory intraneuronal input into superficial pyramidal cells did not survive correction for multiple comparisons and were not correlated with the antidepressant response. These results provide evidence that the antidepressant effects of ketamine may be mediated by acute fronto-parietal connectivity and GABA receptor dynamics. Furthermore, it supports the large body of literature suggesting the acute mechanism underlying ketamine’s antidepressant properties is related to GABA-A and AMPA receptors rather than NMDA receptor antagonism.
- 13 October 2021
- Published by Springer Nature in Brain Topography
- Vol. 34 (6) , 863-880
Effects of Ketamine and Midazolam on Simultaneous EEG/fMRI Data During Working Memory Processes
Reliable measures of cognitive brain activity from functional neuroimaging techniques may provide early indications of efficacy in clinical trials. Functional magnetic resonance imaging and electroencephalography provide complementary spatiotemporal information and simultaneous recording of these two modalities can remove inter-session drug response and environment variability. We sought to assess the effects of ketamine and midazolam on simultaneous electrophysiological and hemodynamic recordings during working memory (WM) processes. Thirty participants were included in a placebo-controlled, three-way crossover design with ketamine and midazolam. Compared to placebo, ketamine administration attenuated theta power increases and alpha power decreases and midazolam attenuated low beta band decreases to increasing WM load. Additionally, ketamine caused larger blood-oxygen-dependent (BOLD) signal increases in the supplementary motor area and angular gyrus, and weaker deactivations of the default mode network (DMN), whereas no difference was found between midazolam and placebo. Ketamine administration caused positive temporal correlations between frontal-midline theta (fm-theta) power and the BOLD signal to disappear and attenuated negative correlations. However, the relationship between fm-theta and the BOLD signal from DMN areas was maintained in some participants during ketamine administration, as increasing theta strength was associated with stronger BOLD signal reductions in these areas. The presence of, and ability to manipulate, both positive and negative associations between the BOLD signal and fm-theta suggest the presence of multiple fm-theta components involved in WM processes, with ketamine administration disrupting one or more of these theta-linked WM strategies.
- 13 October 2021
- Published by Springer Nature in Brain Topography
- Vol. 34 (6) , 863-880
Effects of Ketamine and Midazolam on Simultaneous EEG/fMRI Data During Working Memory Processes
Reliable measures of cognitive brain activity from functional neuroimaging techniques may provide early indications of efficacy in clinical trials. Functional magnetic resonance imaging and electroencephalography provide complementary spatiotemporal information and simultaneous recording of these two modalities can remove inter-session drug response and environment variability. We sought to assess the effects of ketamine and midazolam on simultaneous electrophysiological and hemodynamic recordings during working memory (WM) processes. Thirty participants were included in a placebo-controlled, three-way crossover design with ketamine and midazolam. Compared to placebo, ketamine administration attenuated theta power increases and alpha power decreases and midazolam attenuated low beta band decreases to increasing WM load. Additionally, ketamine caused larger blood-oxygen-dependent (BOLD) signal increases in the supplementary motor area and angular gyrus, and weaker deactivations of the default mode network (DMN), whereas no difference was found between midazolam and placebo. Ketamine administration caused positive temporal correlations between frontal-midline theta (fm-theta) power and the BOLD signal to disappear and attenuated negative correlations. However, the relationship between fm-theta and the BOLD signal from DMN areas was maintained in some participants during ketamine administration, as increasing theta strength was associated with stronger BOLD signal reductions in these areas. The presence of, and ability to manipulate, both positive and negative associations between the BOLD signal and fm-theta suggest the presence of multiple fm-theta components involved in WM processes, with ketamine administration disrupting one or more of these theta-linked WM strategies.
- 6 March 2020
- Published by Springer Nature in Brain Topography
- Vol. 33 (3) , 303-316
On the Quality, Statistical Efficiency, and Safety of Simultaneously Recorded Multiband fMRI/EEG
The recent development of multiband functional magnetic resonance imaging (MB-fMRI) allows for the reduction of sampling period by simultaneously exciting multiple slices—the number of which is referred to as the multiband factor. Simultaneously recorded electroencephalography (EEG)/MB-fMRI has yet to be validated for data quality against conventional single band (SB)-fMRI. Pilot scans were conducted on phantoms twice and on a healthy volunteer to ensure no heating effects. In the main study, two thermometer probes were attached to 16 healthy individuals (ages 20–39, 9 females) whilst they completed two sets of 16-min resting-state and two sets of 9-min n-back task scans—each set consisting of one MB4 and one SB pulse sequence. No heating effects were reported and thermometer data showed mean increases of < 1.0 °C. Minimal differences between the two scan types were found in EEG channel variance and spectra. Expected decreases in MB4-fMRI tSNR were observed. In n-back task scans, little to no differences were detected in both EEG source analyses and fMRI local analyses for mixed effects. Resting-state posterior cingulate cortex seed-based analyses of the default mode network along with EEG-informed fMRI analysis of the occipital alpha anticorrelation effect showed improved statistical and spatial sensitivity at lower scan durations. Using EEG/MB4-fMRI for n-back tasks provided no statistical advantages nor disadvantages. However, for studying the resting-state, MB4-fMRI potentially allows for reduced scanning durations for equivalent statistical significance to be obtained or alternatively, larger effect sizes for the same scanning duration. As such, simultaneous EEG/MB4-fMRI is a viable alternative to EEG/SB-fMRI.
- 6 March 2020
- Published by Springer Nature in Brain Topography
- Vol. 33 (3) , 303-316
On the Quality, Statistical Efficiency, and Safety of Simultaneously Recorded Multiband fMRI/EEG
The recent development of multiband functional magnetic resonance imaging (MB-fMRI) allows for the reduction of sampling period by simultaneously exciting multiple slices—the number of which is referred to as the multiband factor. Simultaneously recorded electroencephalography (EEG)/MB-fMRI has yet to be validated for data quality against conventional single band (SB)-fMRI. Pilot scans were conducted on phantoms twice and on a healthy volunteer to ensure no heating effects. In the main study, two thermometer probes were attached to 16 healthy individuals (ages 20–39, 9 females) whilst they completed two sets of 16-min resting-state and two sets of 9-min n-back task scans—each set consisting of one MB4 and one SB pulse sequence. No heating effects were reported and thermometer data showed mean increases of < 1.0 °C. Minimal differences between the two scan types were found in EEG channel variance and spectra. Expected decreases in MB4-fMRI tSNR were observed. In n-back task scans, little to no differences were detected in both EEG source analyses and fMRI local analyses for mixed effects. Resting-state posterior cingulate cortex seed-based analyses of the default mode network along with EEG-informed fMRI analysis of the occipital alpha anticorrelation effect showed improved statistical and spatial sensitivity at lower scan durations. Using EEG/MB4-fMRI for n-back tasks provided no statistical advantages nor disadvantages. However, for studying the resting-state, MB4-fMRI potentially allows for reduced scanning durations for equivalent statistical significance to be obtained or alternatively, larger effect sizes for the same scanning duration. As such, simultaneous EEG/MB4-fMRI is a viable alternative to EEG/SB-fMRI.